NITI Aayog CEO Amitabh Kant 
Business

India scaling up production of APIs: NITI Aayog CEO Amitabh Kant

India, a global hub for generic drugs, has launched a new scheme to boost production of active pharmaceutical ingredients (APIs) that are greatly dependent on the Chinese supply chain, according to NITI Aayog CEO Amitabh Kant.

migrator

New Delhi

Speaking at the 14th Annual BioPharma and Healthcare Summit, he said India is now gearing up for innovation in its pharmaceutical ecosystem focusing on speedy and scaled up delivery of new vaccines and personalised medicines.

He said India has launched a new scheme to boost production of active pharmaceutical ingredients that are greatly dependent on the Chinese supply chain. “We are planning to do complete manufacturing in India,” he said at the recently-held virtual summit organised by the USA-India Chamber of Commerce.

The summit was attended by major players from the US pharma sector, whose combined annual R&D budget is over $45 billion.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Tiruchendur-Nellai passenger trains cancelled for three days due to track maintenance

Filmmaker Bharathiraja to be laid to rest with state honours in Theni today

Fresh setback to TMC as Rajya Sabha MP Prakash Baraik resigns from Upper House

SC to hear Natarajan’s plea against rejection of RS candidature on Friday

Strait of Hormuz "closed to all vessels," says Iran's IRGC amid escalating tensions